2. Search Result
Search Result
Pathways Recommended: Antibody-drug Conjugate/ADC Related
Results for "

folate conjugate

" in MedChemExpress (MCE) Product Catalog:

24

Inhibitors & Agonists

13

Biochemical Assay Reagents

2

Peptides

1

Inhibitory Antibodies

1

Natural
Products

1

Click Chemistry

8

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P99612
    Farletuzumab ecteribulin

    MORAb-202

    		 Antibody-Drug Conjugates (ADCs) Cancer
    Farletuzumab ecteribulin (MORAb-202) is an antibody-drug conjugate (ADC), consisting of the humanized anti-human folate receptor alpha (FRA) antibody Farletuzumab (HY-P99153) conjugated via reduced interchain disulfide bonds to Mal-PEG2-Val-Cit-PAB-eribulin. Farletuzumab ecteribulin has a agent-to-antibody ratio of 4.0. Farletuzumab ecteribulin is highly cytotoxic to FRA-positive cells in vitro. Farletuzumab ecteribulin has potent antitumor activity.
    Farletuzumab ecteribulin
  • HY-155882
    mPEG-amine (MW 750)

    mPEG-NH2 (MW 750)

    		 Biochemical Assay Reagents Cancer
    mPEG-amine (MW 750) can synthesize folate-conjugated polymer micelles for encapsulation of anticancer agent 9-nitrocamptothecin (HY-16560). folate-conjugated polymer micelles are effective carriers of insoluble anticancer drugs, which can avoid macrophages and play a role in endocytosis of tumor cells mediated by folate receptors (FR).
    mPEG-amine (MW 750)
  • HY-155881
    mPEG-amine (MW 550)

    mPEG-NH2 (MW 550)

    		 Biochemical Assay Reagents Cancer
    mPEG-amine (MW 550) can synthesize folate-conjugated polymer micelles for encapsulation of anticancer agent 9-nitrocamptothecin (HY-16560). folate-conjugated polymer micelles are effective carriers of insoluble anticancer drugs, which can avoid macrophages and play a role in endocytosis of tumor cells mediated by folate receptors (FR).
    mPEG-amine (MW 550)
  • HY-16181
    EC-0225

    		Folate Receptor (FR) Microtubule/Tubulin DNA Alkylator/Crosslinker Cancer
    EC-0225, a folate conjugate of two agents- one a potent microtubule inhibiting agent, and the second a DNA alkylating agent. EC-0225 inhibits the growth of folate receptor (FR)-positive KB cells with an IC50 of ~1 nM. EC-0225 can be selectively delivered to advanced FR-positive tumors without causing overt toxicity, such as lung carcinoma .
    EC-0225
  • HY-W440715
    Cholesterol-PEG-Folate, MW 2000

    		Liposome Others
    Cholesterol-PEG-Folate, MW 2000 is an excipient and can be used for the preparation of folate-conjugated PEG-liposomes .
    Cholesterol-PEG-Folate, MW 2000
  • HY-128937
    EC1454

    		Liposome Folate Receptor (FR) Cancer
    EC1454 is a peptide compound with anticancer activity that targets folate receptor-expressing cancers. EC1454 is a folate-tubulysin conjugate that can be used to prepare drug delivery conjugates for targeted therapy .
    EC1454
  • HY-155880
    mPEG-amine (MW 350)

    mPEG-NH2 (MW 350)

    		 Biochemical Assay Reagents Cancer
    mPEG-amine (MW 350) can synthesize folate-conjugated polymer micelles for encapsulation of anticancer agent 9-nitrocamptothecin (HY-16560). folate-conjugated polymer micelles are effective carriers of insoluble anticancer drugs, which can avoid macrophages and play a role in endocytosis of tumor cells mediated by folate receptors (FR).
    mPEG-amine (MW 350)
  • HY-155883
    mPEG-amine (MW 3400)

    mPEG-NH2 (MW 3400)

    		 Biochemical Assay Reagents Cancer
    mPEG-amine (MW 3400) can synthesize folate-conjugated polymer micelles for encapsulation of anticancer agent 9-nitrocamptothecin (HY-16560). folate-conjugated polymer micelles are effective carriers of insoluble anticancer drugs, which can avoid macrophages and play a role in endocytosis of tumor cells mediated by folate receptors (FR).
    mPEG-amine (MW 3400)
  • HY-N16022
    N-TETAMINE-pSar45-Folate

    		Biochemical Assay Reagents Others
    N-TETAMINE-pSar45-Folate is a lipid that is composed of a Folic acid (HY-16637) unit conjugated to a N-TETAMINE-pSar45. N-TETAMINE-pSar45-Folate can be used to prepare lipid nanoparticles for drug delivery.
    N-TETAMINE-pSar45-Folate
  • HY-155884
    mPEG-amine (MW 4000)

    mPEG-NH2 (MW 4000)

    		 Biochemical Assay Reagents Cancer
    mPEG-amine (MW 4000) can be used to synthesize folate-conjugated polymer micelles for encapsulating anticancer agent 9-nitrocamptothecin (HY-16560). folate-conjugated polymer micelles are effective carriers of insoluble anticancer drugs, which can avoid macrophages and play a role in endocytosis of tumor cells mediated by folate receptors (FR).
    mPEG-amine (MW 4000)
  • HY-128940
    EC089

    		ADC Linker Cancer
    EC089 is a cleavable linker used in conjugates of tubulysins and folates, and extracted from patent WO2011069116A1 .
    EC089
  • HY-W115607
    PEG-bis-amine (MW 8000)

    Poly(ethylene glycol)-bis-amine (MW 8000)

    		 Biochemical Assay Reagents Cancer
    PEG-bis-amine (MW 8000) synthesizes folate-conjugated polymeric micelles for encapsulation of the anticancer agent 9-nitrocamptothecin HY-16560 (HY-16560). Folic acid-conjugated polymer micelles are effective carriers of insoluble anticancer drugs, which can avoid macrophages and play a role in endocytosis of tumor cells mediated by folate receptors (FR).
    PEG-bis-amine (MW 8000)
  • HY-W591632
    PEG-bis-amine (MW 1000)

    Poly(ethylene glycol)-bis-amine (MW 1000)

    		 Biochemical Assay Reagents Cancer
    PEG-bis-amine (MW 1000) synthesizes folate-conjugated polymeric micelles for encapsulation of the anticancer agent 9-nitrocamptothecin HY-16560 (HY-16560). Folic acid-conjugated polymer micelles are effective carriers of insoluble anticancer drugs, which can avoid macrophages and play a role in endocytosis of tumor cells mediated by folate receptors (FR).
    PEG-bis-amine (MW 1000)
  • HY-114306
    EC0489

    		Antifolate Cancer
    EC0489, a conjugate of folic acid and desacetyl vinblastine hydrazide, is a high-affinity ligand for the folate receptor (FR). Refractory or metastatic Tumor . Small molecule-agent conjugate (SMDC) .
    EC0489
  • HY-172351A
    PEG-bis-amine (MW 6000)

    		Biochemical Assay Reagents Cancer
    PEG-bis-amine (MW 6000) synthesizes folate-conjugated polymeric micelles for encapsulation of the anticancer agent Rubitecan (HY-16560) .
    PEG-bis-amine (MW 6000)
  • HY-172351
    PEG-bis-amine (MW 400)

    		Biochemical Assay Reagents Cancer
    PEG-bis-amine (MW 400) synthesizes folate-conjugated polymeric micelles for encapsulation of the anticancer agent Rubitecan (HY-16560) .
    PEG-bis-amine (MW 400)
  • HY-172351B
    PEG-bis-amine (MW 10000)

    		Biochemical Assay Reagents Cancer
    PEG-bis-amine (MW 10000) synthesizes folate-conjugated polymeric micelles for encapsulation of the anticancer agent Rubitecan (HY-16560) .
    PEG-bis-amine (MW 10000)
  • HY-138484
    Folate-PEG3-amine

    		ADC Linker Cancer
    Folate-PEG3-amine is a cleavable 3 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .
    Folate-PEG3-amine
  • HY-129880
    Desacetylvinblastine hydrazide

    Deacetylvinblastine hydrazide; DAVLBH

    		 Microtubule/Tubulin Cancer
    Desacetylvinblastine hydrazide (Deacetylvinblastine hydrazide; DAVLBH) is an active component of EC145, a folate-targeted drug conjugate. Desacetylvinblastine hydrazide interferes with the formation of the mitotic spindle, and thus inhibits cell division and leads to cell death. Desacetylvinblastine hydrazide exhibits antitumor activity against folate receptor (FR)-positive tumor .
    Desacetylvinblastine hydrazide
  • HY-132258A
    Mirvetuximab soravtansine (solution)
    2 Publications Verification

    IMGN853 (solution)

    		 Antibody-Drug Conjugates (ADCs) Antifolate Cancer
    Mirvetuximab soravtansine (IMGN853) solution is an anti-folate receptor α (FRα) antibody drug-conjugate (ADC) consisting of the cytotoxic maytansinoid, DM4, covalently linked to the humanized monoclonal antibody M9346A, and the drug-linker conjugate for ADC is sulfo-SPDB-DM4 (HY-101141). Mirvetuximab soravtansine selectively binds to folate receptor 1 (FOLR1). Mirvetuximab soravtansine has an anti-proliferative effect via growth arrest and augmented DNA damage .
    Mirvetuximab soravtansine (solution)
  • HY-P10762
    Ricorfotide vedotin

    CBP-1008; LDC 10B

    		 Peptide-Drug Conjugates (PDCs) Folate Receptor (FR) TRP Channel Cancer
    Ricorfotide vedotin (CBP-1008) is a dual-ligand peptide-drug conjugate (PDC) conjugated to MMAE (HY-15162), targeting Folate receptor α (FRα) and TRPV6. Ricorfotide vedotin binds to FRα with high affinity and TRPV6 with low affinity. Ricorfotide vedotin has antitumor activity, and can be used in advanced solid tumor research (eg: colorectal cancer, breast cancer, non-small cell lung cancer, ovarian cancer, adrenocortical carcinoma and follicular dendritic cell sarcoma) .
    Ricorfotide vedotin
  • HY-W053583
    Tetraxetan
    1 Publications Verification

    DOTA

    		 Biochemical Assay Reagents Radionuclide-Drug Conjugates (RDCs) Cancer
    Tetraxetan (DOTA) is a macrocyclic chelating agent. Tetraxetan can form stable coordination complexes with a variety of metal ions (e.g., 68Ga, 111In, 177Lu). Tetraxetan can be conjugated with targeting molecules (e.g., RGD peptide, folic acid) to enable the complex to target specific biomolecules or cells. Tetraxetan can be used for imaging studies of tumors, including melanoma and folate receptor-positive tumors (e.g., cervical cancer) .
    Tetraxetan
  • HY-W006064
    L-Propargylglycine
    1 Publications Verification

    (S)-2-Aminopent-4-ynoic acid

    		 Amino Acid Derivatives Others
    (S)-2-Aminopent-4-ynoic acid is a synthetic amino acid. (S)-2-Aminopent-4-ynoic acid can be used in synthesis of folate-conjugates and corresponding metal-chelate complexes . (S)-2-Aminopent-4-ynoic acid is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    L-Propargylglycine
  • HY-W053583R
    Tetraxetan (Standard)

    DOTA (Standard)

    		 Biochemical Assay Reagents Reference Standards Radionuclide-Drug Conjugates (RDCs) Cancer
    Tetraxetan (Standard) is the analytical standard of Tetraxetan (HY-W053583). This product is intended for research and analytical applications. Tetraxetan (DOTA) is a macrocyclic chelating agent. Tetraxetan can form stable coordination complexes with a variety of metal ions (e.g., 68Ga, 111In, 177Lu). Tetraxetan can be conjugated with targeting molecules (e.g., RGD peptide, folic acid) to enable the complex to target specific biomolecules or cells. Tetraxetan can be used for imaging studies of tumors, including melanoma and folate receptor-positive tumors (e.g., cervical cancer) .
    Tetraxetan (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: